About the author
Claudia Zylberberg, Ph.D. is a biotech leader with more than 30 years in the field. She is the founder and CEO of Akron Biotechnology, an innovative company that develops, manufactures and markets ancillary materials and novel products/tools under cGMP compliance for tissue, cell and gene therapies serving the regenerative medicine industry from development to bedside.
Under Dr. Zylberberg’s leadership, Akron has received grants from the Department of Defense and the National Institutes of Health, among other entities. She has developed various patented and patent-pending technologies, including cryopreservation media, oligonucleotides, and recombinant protein formulations, and has coauthored numerous academic articles published in peer reviewed journals. Dr. Zylberberg has engaged in several multi-stakeholder initiatives to formalize and strengthen the regenerative medicine industry, including the Standards Coordinating Body (SCB), which she cofounded.
She began her career at Nabi Biopharmaceuticals, specializing in the manufacture of human plasma-derived products. Her background in cell processing and work in the blood and plasma industry enabled her to cofound AssumeImmune, an adult stem cell bank, and to later incorporate blood-derived products into Akron’s portfolio. Her extensive experience in cell and tissue banking, process development, and recombinant protein manufacturing has been instrumental for the development of new products critical to the advancement of the regenerative medicine industry.